Koss-Olinger Consulting’s Editas Medicine EDIT Stock Holding History

Koss-Olinger Consulting’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,000	Closed	-$22K	–	286
2025 Q3	$22K	Hold	10,000	–	–	﹤0.01%	311
2025 Q2	$22K	Hold	10,000	–	–	﹤0.01%	314
2025 Q1	$12K	Hold	10,000	–	–	﹤0.01%	307
2024 Q4	$13K	Hold	10,000	–	–	﹤0.01%	184
2024 Q3	$34K	Hold	10,000	–	–	﹤0.01%	271
2024 Q2	$47K	Buy	+10,000	New	+$56.4K	﹤0.01%	259
2024 Q1	–	Sell	-10,000	Closed	-$101K	–	116
2023 Q4	$101K	Hold	10,000	–	–	0.01%	305
2023 Q3	$78K	Hold	10,000	–	–	0.01%	267
2023 Q2	$82K	Hold	10,000	–	–	0.01%	275
2023 Q1	$73K	Buy	+10,000	New	+$88.9K	0.01%	255
2021 Q3	–	Sell	-32,100	Closed	-$1.82M	–	248
2021 Q2	$1.82M	Hold	32,100	–	–	0.27%	41
2021 Q1	$1.35M	Buy	+32,100	New	+$1.83M	0.23%	48

Other funds holding EDIT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Koss-Olinger Consulting's EDIT Position: Q4 2025 in Review

Koss-Olinger Consulting sold out of Editas Medicine (EDIT) in Q4 2025, closing a stake of 10,000 shares — an estimated $22K sold.

Koss-Olinger Consulting first reported a position in EDIT in Q1 2021 and held it in 12 quarters. The position peaked at $1.82M in Q2 2021. 197 funds tracked by Wall St. Rank hold EDIT as of Q4 2025.

Koss-Olinger Consulting reported no remaining Editas Medicine position as of Q4 2025 after selling out during the quarter.
Koss-Olinger Consulting sold 10,000 Editas Medicine shares in Q4 2025, an estimated $22K.
Koss-Olinger Consulting first reported a position in Editas Medicine in Q1 2021 and held it in 12 quarters.
Koss-Olinger Consulting's Editas Medicine position peaked at $1.82M in Q2 2021.
197 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2025.

Based on Koss-Olinger Consulting's 13F filing for Q4 2025, filed 10 Feb 2026.